Avity Investment Management Inc. Decreases Stake in Thermo Fisher Scientific Inc. $TMO

Avity Investment Management Inc. reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 16.2% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 39,205 shares of the medical research company’s stock after selling 7,559 shares during the period. Avity Investment Management Inc.’s holdings in Thermo Fisher Scientific were worth $15,896,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Atwood & Palmer Inc. lifted its position in shares of Thermo Fisher Scientific by 0.5% during the second quarter. Atwood & Palmer Inc. now owns 54,062 shares of the medical research company’s stock worth $21,920,000 after purchasing an additional 274 shares during the last quarter. Granite Bay Wealth Management LLC lifted its position in shares of Thermo Fisher Scientific by 33.1% during the second quarter. Granite Bay Wealth Management LLC now owns 13,667 shares of the medical research company’s stock worth $5,541,000 after purchasing an additional 3,395 shares during the last quarter. RMR Wealth Builders lifted its position in shares of Thermo Fisher Scientific by 24.6% during the second quarter. RMR Wealth Builders now owns 3,574 shares of the medical research company’s stock worth $1,449,000 after purchasing an additional 705 shares during the last quarter. NBC Securities Inc. lifted its position in shares of Thermo Fisher Scientific by 9.4% during the second quarter. NBC Securities Inc. now owns 2,741 shares of the medical research company’s stock worth $1,111,000 after purchasing an additional 235 shares during the last quarter. Finally, Apella Capital LLC lifted its position in shares of Thermo Fisher Scientific by 6.7% during the second quarter. Apella Capital LLC now owns 640 shares of the medical research company’s stock worth $268,000 after purchasing an additional 40 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares in the company, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $479.48 on Monday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $623.77. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The firm has a market capitalization of $181.06 billion, a PE ratio of 27.73, a P/E/G ratio of 2.56 and a beta of 0.75. The company’s 50 day simple moving average is $466.86 and its 200 day simple moving average is $450.58.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter last year, the business earned $5.37 earnings per share. The business’s revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.95%.

Wall Street Analyst Weigh In

TMO has been the topic of several research analyst reports. UBS Group increased their price target on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a research report on Thursday, July 24th. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 24th. Royal Bank Of Canada set a $561.00 price objective on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. Wall Street Zen lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, September 7th. Finally, Evercore ISI dropped their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 8th. Seventeen analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $592.24.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.